GordonMD Global Investments LP
CIK 2039349 · View on SEC EDGAR ↗
- Portfolio value
- $206.7M
- Positions
- 16
- As of
- June 30, 2026
#6,354 of 9,443 by 13F value · top 67.3%
Portfolio value QoQ: +43.9% 13F does not disclose cash
- Top 10 holdings weight
- 83.89%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 16
- Effective number of positions
- 10.4
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 2.95% Est. buys $47,813,775 · sells $5,162,038
- New positions
- 1
- Increased
- 4
- Decreased
- 2
- Closed
- 1
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Sector breakdown
Healthcare
100.0%
Full portfolio 16 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics, Inc. - Common Stock | $37,821,328 | 18.30% | 4,244,818 | $1,188,549 | |||
| PYXS Pyxis Oncology, Inc. - Common Stock | $30,174,976 | 14.60% | 10,024,909 | $24,157,046 | Up ×1 | ||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $24,501,508 | 11.86% | 723,185 | $2,286,502 | Down ×2 | ||
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $16,360,991 | 7.92% | 2,402,495 | $10,739,988 | Up ×2 | ||
| VIR Vir Biotechnology, Inc. - Common Stock | $13,792,695 | 6.67% | 1,353,552 | $186,469 | Down ×1 | ||
| ALLO Allogene Therapeutics, Inc. - Common Stock | $11,019,840 | 5.33% | 5,298,000 | $7,530,640 | Up ×1 | ||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $10,408,381 | 5.04% | 279,720 | $5,006,243 | Up ×1 | ||
| EDIT Editas Medicine, Inc. - Common Stock | $10,131,480 | 4.90% | 3,127,000 | Up ×1 | |||
| RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $9,653,082 | 4.67% | 289,101 | $3,596,416 | |||
| BLCO Bausch + Lomb Corporation Common Shares | $9,496,696 | 4.60% | 573,472 | $378,491 | |||
| AMGN Amgen Inc. - Common Stock | $7,319,169 | 3.54% | 20,212 | $207,577 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $7,287,500 | 3.53% | 132,500 | $773,800 | |||
| SION Sionna Therapeutics, Inc. - Common Stock | $5,982,640 | 2.89% | 136,000 | $530,400 | |||
| INCY Incyte Corporation - Common Stock | $4,908,488 | 2.38% | 43,300 | $833,092 | |||
| CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $4,751,779 | 2.30% | 126,985 | $139,684 | |||
| INSM Insmed Incorporated - Common Stock | $3,047,946 | 1.47% | 28,587 | $-1,626,600 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| EDIT | $10,131,480 | 3,127,000 | 4.90% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| TEVA | Bought more | +1.1M | +$10.7M |
| ALLO | Bought more | +3.9M | +$7.5M |
| CLDX | Bought more | +109K | +$5.0M |
| RARE | Price move only | +0 | +$3.6M |
| TSHA | Trimmed | -14K | +$2.3M |
| INSM | Price move only | +0 | -$1.6M |
| KYTX | Price move only | +0 | +$1.2M |
| INCY | Price move only | +0 | +$833K |
| SRRK | Price move only | +0 | +$774K |
| SION | Price move only | +0 | +$530K |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| TARS | June 30, 2026 | 42,680 | $2,994,002 | 14.8% |